Detalhe da pesquisa
1.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Blood
; 2024 04 30.
Artigo
Inglês
| MEDLINE | ID: mdl-38687605
2.
Diagnosis and classification of myelodysplastic syndromes.
Blood
; 142(26): 2247-2257, 2023 12 28.
Artigo
Inglês
| MEDLINE | ID: mdl-37774372
3.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36724453
4.
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Br J Haematol
; 200(4): 451-461, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36335984
5.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31914241
6.
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Haematologica
; 108(11): 3001-3010, 2023 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37259567
7.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ann Hematol
; 102(2): 311-321, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36635381
8.
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Br J Haematol
; 198(1): 114-130, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35362549
9.
Acute myeloid leukemia-induced functional inhibition of healthy CD34+ hematopoietic stem and progenitor cells.
Stem Cells
; 39(9): 1270-1284, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34013984
10.
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
BMC Cancer
; 22(1): 569, 2022 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-35597904
11.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer
; 22(1): 1013, 2022 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36153475
12.
Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients.
Ann Hematol
; 100(10): 2575-2584, 2021 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-34324021
13.
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).
Ann Hematol
; 100(6): 1463-1471, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-33903952
14.
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.
Eur J Haematol
; 107(2): 283-292, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33987857
15.
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Eur J Haematol
; 107(2): 265-274, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33998054
16.
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine.
Br J Haematol
; 190(3): 361-370, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32350858
17.
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.
Br J Haematol
; 191(3): 405-417, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32410281
18.
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Haematologica
; 105(3): 640-651, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31278207
19.
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.
Haematologica
; 105(3): 632-639, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31171638
20.
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Ann Hematol
; 99(7): 1551-1560, 2020 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-32504186